
## George Cholankeril

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/160580/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017–2018. Journal of General Internal Medicine, 2022, 37, 261-263.	2.6	15
2	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. Clinical Gastroenterology and Hepatology, 2022, 20, e1438-e1455.	4.4	49
3	Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS oVâ€2 Infection. Liver Transplantation, 2022, 28, 127-130.	2.4	1
4	Clinical Factors Associated With Lack of Serological Response to SARS oVâ€2 Messenger RNA Vaccine in Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 123-126.	2.4	25
5	Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clinical Transplantation, 2022, , e14646.	1.6	1
6	DETECT: Development of Technologies for Early HCC Detection. Gastroenterology, 2022, 163, 21-27.	1.3	4
7	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
8	Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. Liver International, 2022, 42, 340-349.	3.9	5
9	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplantation Direct, 2022, 8, e1313.	1.6	10
10	Trends in All-Cause and Cause-Specific Mortality Among Individuals With Diabetes Before and During the COVID-19 Pandemic in the U.S Diabetes Care, 2022, 45, e107-e109.	8.6	4
11	Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. Clinical Gastroenterology and Hepatology, 2021, 19, 1499-1501.e2.	4.4	38
12	Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2021, 27, 1602-1609.	1.9	5
13	Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005–2014. Digestive Diseases and Sciences, 2021, 66, 296-307.	2.3	6
14	Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA. Digestive Diseases and Sciences, 2021, 66, 1461-1476.	2.3	11
15	Trends in mortality in hepatitis C infection and alcoholic liver disease based on drug overdose in the United States. Journal of Viral Hepatitis, 2021, 28, 436-439.	2.0	Ο
16	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1240-1247.e5.	4.4	40
17	Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018. American Journal of Gastroenterology, 2021, 116, 1053-1062.	0.4	15
18	Sarcopenia in nonalcoholic fatty liver disease and all ause and causeâ€specific mortality in the United States, Liver International, 2021, 41, 1832-1840.	3.9	35

#	Article	IF	CITATIONS
19	Current Trends in Liver Transplantation for Alcoholic Hepatitis. Clinics in Liver Disease, 2021, 25, 625-634.	2.1	2
20	Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2021, 19, 2664-2666.e2.	4.4	20
21	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. Current Opinion in Infectious Diseases, 2021, 34, 477-482.	3.1	5
22	Gastrointestinal manifestations of coronavirus disease 2019. Current Opinion in Infectious Diseases, 2021, 34, 471-476.	3.1	4
23	NAFLD and HCC: Time to Bridge the Gap. Hepatology, 2021, 74, 2336-2338.	7.3	3
24	Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. Transplant International, 2021, 34, 1971-1983.	1.6	2
25	Impact of COVIDâ€19 Pandemic on Liver Transplantation and Alcoholâ€Associated Liver Disease in the USA. Hepatology, 2021, 74, 3316-3329.	7.3	75
26	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 747-756.	2.2	2
27	Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. Clinical Transplantation, 2021, , e14544.	1.6	1
28	Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. Journal of Palliative Medicine, 2020, 23, 97-106.	1.1	13
29	Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 to 2017. Clinical Gastroenterology and Hepatology, 2020, 18, 992-994.	4.4	6
30	Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. Digestive Diseases and Sciences, 2020, 65, 990-1002.	2.3	17
31	Diet quality and its association with nonalcoholic fatty liver disease and allâ€cause and causeâ€specific mortality. Liver International, 2020, 40, 815-824.	3.9	26
32	Regional Trends in Mortality from Alcohol-Induced Causes in the United States, 2000–2017. Journal of General Internal Medicine, 2020, 35, 2495-2498.	2.6	1
33	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 1556-1568.	7.3	70
34	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. American Journal of Gastroenterology, 2020, 115, 1496-1504.	0.4	40
35	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00165.	2.5	4
36	Decline in Annual Mortality of Hepatitis C Virus–Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. Gastroenterology, 2020, 159, 1558-1560.e2.	1.3	17

GEORGE CHOLANKERIL

#	Article	IF	CITATIONS
37	Implementation and Impact of Universal Preprocedure Testing of Patients for COVID-19 Before Endoscopy. Gastroenterology, 2020, 159, 1586-1588.e4.	1.3	25
38	Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection. American Journal of Gastroenterology, 2020, 115, 1129-1132.	0.4	39
39	The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. Drug and Alcohol Dependence, 2020, 209, 107917.	3.2	5
40	High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California. Gastroenterology, 2020, 159, 775-777.	1.3	198
41	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. Transplantation, 2020, 104, 2221-2224.	1.0	68
42	Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?. American Journal of Gastroenterology, 2020, 115, 1920-1921.	0.4	15
43	Changing Trends in Etiologyâ€Based and Ethnicityâ€Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology, 2019, 69, 1064-1074.	7.3	154
44	Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary. Nutrition and Metabolic Insights, 2019, 12, 117863881984748.	1.9	5
45	Depression is associated with nonâ€alcoholic fatty liver disease among adults in the United States. Alimentary Pharmacology and Therapeutics, 2019, 50, 590-598.	3.7	62
46	Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation. Scientific Reports, 2019, 9, 8312.	3.3	9
47	Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Translational Gastroenterology and Hepatology, 2019, 4, 65-65.	3.0	11
48	Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology, 2019, 157, 1055-1066.e11.	1.3	53
49	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016. Hepatology International, 2019, 13, 205-213.	4.2	63
50	Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. Annals of Hepatology, 2019, 18, 679-684.	1.5	6
51	Trends in hospitalizations for chronic liver diseaseâ€related liver failure in the United States, 2005â€2014. Liver International, 2019, 39, 1661-1671.	3.9	32
52	Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. Diabetologia, 2019, 62, 1185-1194.	6.3	23
53	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases (Basel, Switzerland), 2019, 7, 27.	2.5	36
54	Elevated urinary bisphenol A levels are associated with nonâ€alcoholic fatty liver disease among adults in the United States. Liver International, 2019, 39, 1335-1342.	3.9	44

GEORGE CHOLANKERIL

#	Article	IF	CITATIONS
55	Disparate Trends in Mortality of Etiology-Specific Chronic Liver Diseases Among Hispanic Subpopulations. Clinical Gastroenterology and Hepatology, 2019, 17, 1607-1615.e2.	4.4	19
56	Temporal Trends Associated With the Rise in Alcoholic Liver Disease-related Liver Transplantation in the United States. Transplantation, 2019, 103, 131-139.	1.0	23
57	Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States. Clinical Gastroenterology and Hepatology, 2019, 17, 2379-2381.	4.4	35
58	Increasing Trends in Transplantation of HCV–Positive Livers Into Uninfected Recipients. Clinical Gastroenterology and Hepatology, 2019, 17, 1634-1636.	4.4	15
59	Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. Liver Transplantation, 2019, 25, 399-410.	2.4	24
60	Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2019, 31, 149-156.	1.6	20
61	An Unexpected Colonic Mass. American Journal of Gastroenterology, 2019, 114, 180-181.	0.4	1
62	Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. Hepatology International, 2019, 13, 84-90.	4.2	21
63	Inpatient Outcomes for Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. Journal of Clinical Gastroenterology, 2019, 53, 120-126.	2.2	3
64	Recent advances in liver transplantation with HCV seropositive donors. F1000Research, 2019, 8, 2151.	1.6	1
65	Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus–Infected Donors for Uninfected Recipients. Hepatology, 2018, 68, 792-793.	7.3	1
66	Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy. Digestive Diseases and Sciences, 2018, 63, 1647-1653.	2.3	12
67	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2018, 16, 965-973.e2.	4.4	28
68	Alcoholic Liver Disease Replaces Hepatitis C Virus Infection asÂthe Leading Indication for Liver Transplantation in the UnitedÂStates. Clinical Gastroenterology and Hepatology, 2018, 16, 1356-1358.	4.4	200
69	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology, 2018, 16, 452-453.	4.4	34
70	The Role of Vitamin E in the Treatment of NAFLD. Diseases (Basel, Switzerland), 2018, 6, 86.	2.5	87
71	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases (Basel, Switzerland), 2018, 6, 87.	2.5	14

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

#	Article	IF	CITATIONS
73	When to Initiate Weight Loss Medications in the NAFLD Population. Diseases (Basel, Switzerland), 2018, 6, 91.	2.5	11
74	Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases (Basel,) Tj ETQqO O	0 rgBT/Ove	rlock 10 Tf 50
75	Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology, 2018, 155, 1154-1163.e3.	1.3	166
76	Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	1.4	25
77	Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation. Diseases (Basel,) Tj ETQq1	1 0.784314	rgBT /Overld
78	Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. Medicines (Basel, Switzerland), 2018, 5, 47.	1.4	18
79	The Role of Cannabinoids in the Setting of Cirrhosis. Medicines (Basel, Switzerland), 2018, 5, 52.	1.4	17
80	Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era. Diseases (Basel, Switzerland), 2018, 6, 62.	2.5	16
81	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. Journal of Viral Hepatitis, 2018, 25, 1608-1616.	2.0	13
82	Early Liver Transplantation is a Viable Treatment Option in Severe Acute Alcoholic Hepatitis. Alcohol and Alcoholism, 2018, 53, 716-718.	1.6	13
83	Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States. Journal of General Internal Medicine, 2018, 33, 1423-1425.	2.6	4
84	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. Journal of Clinical and Translational Hepatology, 2018, 6, 1-5.	1.4	20
85	Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World Journal of Gastroenterology, 2018, 24, 315-322.	3.3	15
86	Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. Clinical Gastroenterology and Hepatology, 2017, 15, 313-315.	4.4	12
87	Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding?. Gastroenterology, 2017, 152, 2076.	1.3	9
88	Optimal timing for hepatitis C antiviral therapy in the peritransplant period?. Hepatology, 2017, 66, 1004-1004.	7.3	0
89	Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2017, 112, 1495-1505.	0.4	83
90	Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients. Transplantation, 2017, 101, e349.	1.0	5

GEORGE CHOLANKERIL

#	Article	IF	CITATIONS
91	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Digestive Diseases and Sciences, 2017, 62, 2915-2922.	2.3	192
92	Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast. Hepatology, 2017, 65, 393-393.	7.3	3
93	Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease. Diseases (Basel, Switzerland), 2017, 5, 20.	2.5	10
94	The importance of a multidisciplinary approach to hepatocellular carcinoma. Journal of Multidisciplinary Healthcare, 2017, Volume 10, 95-100.	2.7	52
95	Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. Nutrients, 2017, 9, 1114.	4.1	15
96	Hepatic encephalopathy: what the multidisciplinary team can do. Journal of Multidisciplinary Healthcare, 2017, Volume 10, 113-119.	2.7	6
97	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8263-8276.	3.3	514
98	Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World Journal of Hepatology, 2017, 9, 533.	2.0	140
99	Portomesenteric venous thrombosis complicated by a haemorrhagic shock: a rare complication of laparoscopic gastrectomy. BMJ Case Reports, 2017, 2017, bcr-2016-219167.	0.5	1
100	Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. Journal of Clinical and Translational Hepatology, 2017, 5, 1-5.	1.4	7
101	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. Digestive Diseases and Sciences, 2016, 61, 2505-2515.	2.3	12
102	Trends in Liver Transplantation Multiple Listing Practices Associated With Disparities in Donor Availability: An Endless Pursuit to Implement the Final Rule. Gastroenterology, 2016, 151, 382-386.e2.	1.3	5